Deborah A Elder1, Jessica G Woo, David A D'Alessio. 1. Cincinnati Children's Hospital Medical Center, Department of Pediatrics, Division of Endocrinology, Cincinnati, OH 45229, USA. deborah.elder@cchmc.org
Abstract
BACKGROUND: Adults with type 2 diabetes mellitus (T2DM) have broad impairments in beta-cell function, including severe attenuation of the first-phase insulin response to glucose, and reduced beta-cell mass. In adolescents with T2DM, there is some evidence that beta-cell dysfunction may be less severe. Our objective was to determine beta-cell sensitivity to glucose and maximal insulin secretory capacity (AIR(max)) in teenagers with T2DM. METHODS: Fifteen adolescents with T2DM [11 F/4 M, age 18.4 +/- 0.3 yr, body mass index (BMI) 39.8 +/- 2.2 kg/m(2)] and 10 non-diabetic control subjects (7 F/3 M, age 17.4 +/- 0.5 yr, BMI 41.5 +/- 2.2 kg/m(2)) were studied. T2DM subjects had a mean duration of diabetes of 48.8 +/- 6.4 months, were treated with conventional therapies, and had good metabolic control [hemoglobin A1c (HbA1c) 6.7 +/- 1.2%]. Insulin and C-peptide were determined before and after a graded glucose infusion and after intravenous arginine at a whole blood glucose level of >or=22 mM. RESULTS: The insulin response to increasing plasma glucose concentrations was blunted in the diabetic compared with control subjects (34.8 +/- 11.9 vs. 280.5 +/- 57.8 pmol/mmol; p < 0.0001), and AIR(max) was also significantly reduced in the diabetic group (1868 +/- 330 vs. 4445 +/- 606; p = 0.0005). CONCLUSION: Even adolescents with well-controlled T2DM have severe impairments of insulin secretion. These data support beta-cell dysfunction as central in the pathogenesis of T2DM in young people, and indicate that these abnormalities can develop over a period of just several years.
BACKGROUND: Adults with type 2 diabetes mellitus (T2DM) have broad impairments in beta-cell function, including severe attenuation of the first-phase insulin response to glucose, and reduced beta-cell mass. In adolescents with T2DM, there is some evidence that beta-cell dysfunction may be less severe. Our objective was to determine beta-cell sensitivity to glucose and maximal insulin secretory capacity (AIR(max)) in teenagers with T2DM. METHODS: Fifteen adolescents with T2DM [11 F/4 M, age 18.4 +/- 0.3 yr, body mass index (BMI) 39.8 +/- 2.2 kg/m(2)] and 10 non-diabetic control subjects (7 F/3 M, age 17.4 +/- 0.5 yr, BMI 41.5 +/- 2.2 kg/m(2)) were studied. T2DM subjects had a mean duration of diabetes of 48.8 +/- 6.4 months, were treated with conventional therapies, and had good metabolic control [hemoglobin A1c (HbA1c) 6.7 +/- 1.2%]. Insulin and C-peptide were determined before and after a graded glucose infusion and after intravenous arginine at a whole blood glucose level of >or=22 mM. RESULTS: The insulin response to increasing plasma glucose concentrations was blunted in the diabetic compared with control subjects (34.8 +/- 11.9 vs. 280.5 +/- 57.8 pmol/mmol; p < 0.0001), and AIR(max) was also significantly reduced in the diabetic group (1868 +/- 330 vs. 4445 +/- 606; p = 0.0005). CONCLUSION: Even adolescents with well-controlled T2DM have severe impairments of insulin secretion. These data support beta-cell dysfunction as central in the pathogenesis of T2DM in young people, and indicate that these abnormalities can develop over a period of just several years.
Authors: M M Byrne; J Sturis; S S Fajans; F J Ortiz; A Stoltz; M Stoffel; M J Smith; G I Bell; J B Halter; K S Polonsky Journal: Diabetes Date: 1995-06 Impact factor: 9.461
Authors: W H Herman; S S Fajans; F J Ortiz; M J Smith; J Sturis; G I Bell; K S Polonsky; J B Halter Journal: Diabetes Date: 1994-01 Impact factor: 9.461
Authors: Deborah A Elder; Patricia M Herbers; Tammy Weis; Debra Standiford; Jessica G Woo; David A D'Alessio Journal: J Pediatr Date: 2012-01-10 Impact factor: 4.406
Authors: Fida Bacha; Laura Pyle; Kristen Nadeau; Leona Cuttler; Robin Goland; Morey Haymond; Lynne Levitsky; Jane Lynch; Ruth S Weinstock; Neil H White; Sonia Caprio; Silva Arslanian Journal: Pediatr Diabetes Date: 2012-02-15 Impact factor: 4.866
Authors: Henry Zelada; Andres M Carnero; César Miranda-Hurtado; Diana Condezo-Aliaga; Cesar Loza-Munarriz; Pedro Aro-Guardia; Helard Manrique Journal: J Clin Transl Endocrinol Date: 2016-05-16
Authors: Silva Arslanian; Fida Bacha; Margaret Grey; Marsha D Marcus; Neil H White; Philip Zeitler Journal: Diabetes Care Date: 2018-12 Impact factor: 19.112
Authors: Joon Young Kim; Michael I Goran; Claudia M Toledo-Corral; Marc J Weigensberg; Myunghan Choi; Gabriel Q Shaibi Journal: Diabetes Care Date: 2013-01-11 Impact factor: 19.112